BioCryst Pharmaceuticals Inc. (BCRX)
Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround
BioCryst (BCRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT Company Participants Charles Gayer - President Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Good morning, everyone, and thanks so much for joining us for our next session. I'm Steve Seedhouse with the Cantor Biotech team.
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Babar Ghias - CFO & Head of Corporate Development Charles K. Gayer - President Donald S.
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.06 per share a year ago.
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Buy Stocks for June 4th
BCRX, OPRX, BWB, PLMR and RACE have been added to the Zacks Rank #1 (Strong Buy) List on June 4, 2025.
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade
The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Best Momentum Stocks to Buy for May 9th
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
New Strong Buy Stocks for May 9th
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
